Study of LPM6690176 with chemo and Avastin for RAS-mutant colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called LPM6690176 combined with chemotherapy and Avastin (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. It may be an option for those who haven't had treatment for their advanced cancer or have already tried one line of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with colorectal cancer that has spread to other parts of the body and has a RAS mutation
- You haven't had any treatment for your advanced cancer, or you have tried only one prior treatment and it stopped working or caused side effects
- You are generally up and active (ECOG score 0 or 1), meaning you can take care of yourself and do daily activities
- You do not have certain other cancers, serious heart or lung problems, or a high risk of bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
This trial is for people with advanced colorectal cancer that has stopped responding to first-line treatment. It tests a combination of chemotherapy, a targeted therapy, and an investigational drug to see if it can help slow the cancer's growth.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests whether a combination of targeted radiation (SBRT), chemotherapy (CAPEOX), a biologic drug (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of advanced colorectal cancer that cannot be removed by surgery. It is for patients whose tumors have a RAS gene mutation and are microsatellite stable (MSS).
This trial tests a new drug combination (QL1706 and bevacizumab) for people with advanced colorectal cancer that has a specific genetic feature (MSI-H/dMMR). It aims to see if this treatment can help shrink or control the cancer.
This trial compares two treatments for people with a specific type of advanced colorectal cancer that has a RAS mutation. It tests if fruquintinib works as well as the standard combination of bevacizumab and chemotherapy in people who have already had one round of chemotherapy.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.